You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 3
  • #216 Implementation of a sentinel lymph node algorithm for surgical staging of endometrial carcinoma: self-reported lower extremity lymphedema and quality of life – a population based cross-sectional study

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
10. Quality of Life After Treatment
#216 Implementation of a sentinel lymph node algorithm for surgical staging of endometrial carcinoma: self-reported lower extremity lymphedema and quality of life – a population based cross-sectional study
Free
  1. Pernille Bjerre Trent1,
  2. Nina Jebens Nordskar2,
  3. Knut Reidar Wangen3,
  4. Ida Engeskaug1,
  5. Linn Opheim1,
  6. Guro Aune2,
  7. Anne Cathrine Staff3,
  8. Lene Thorsen1,
  9. Ragnhild Sørum Falk4 and
  10. Ane Gerda Zahl Eriksson1
  1. 1Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  2. 2St Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway
  3. 3Faculty of Medicine, University of Oslo, Oslo, Norway
  4. 4Research Support Services, Oslo University Hospital, Oslo, Norway

Abstract

Introduction/Background Sentinel lymph node (SLN) biopsy has replaced lymphadenectomy (LND) in staging of endometrial carcinoma (EC). The aims of this study were to:

  1. Explore prevalence of lower extremity lymphedema (LEL) in EC survivors stratified by nodal assessment (LND, SLN and hysterectomy alone).

  2. Identify patient- and treatment-related factors associated with LEL.

  3. Compare quality of life (QoL) using novel thresholds of clinical importance.

  4. Assess correlation between different questionnaires.

Methodology Women operated for EC in 2006–2021 retrospectivly completed the Lower Extremity Lymphedema Screening Questionnaire (LELSQ), EORTC QLQ-C30, QLQ-EN24 and EQ-5D-5L. Appropriate statistics were applied to assess study aims.

Abstract #216 Figure 1
Abstract #216 Figure 1

Subgroup analysis of LEL prevalence by musculoskeletal complaints stratified by nodal assessment

Results Of 2156 invited survivors, 61% participated in the study, 1127 (99%) were evaluable by LELSQ. LEL prevalence was 51%, 36% and 40% after LND, SLN and hysterectomy, respectively (p<0.001). Higher BMI, LND and chemotherapy were associated with LEL; OR 1.07 (95% CI 1.05–1.09), 1.42 (95% CI 1.03–1.97) and 1.43 (95% CI 1.08–1.89) respectively. Subgroup analysis demonstrated that musculoskeletal complaints were more prevalent in patients reporting LEL (figure 1). In women with musculoskeletal complaints the prevalence of LEL did not differ between nodal assessment groups; 59%, 50% and 53% after LND, SLN and hysterectomy (p=0.115), respectively, compared to 39%, 17% and 18% (p<0.001) in women without musculosceletal complaints. Women with LEL had worse QoL in all domains than those without LEL (p<0.001). Spearman’s correlation between questionnaires varied from 0.67 to 0.83.

Conclusion For the whole cohort, SLN implementation is not associated with increased LEL prevalence compared to hysterectomy alone, but is associated with a significantly lower prevalence compared to LND. However, this difference was not seen in women reporting musculoskeletal complaints. Available questionnaires may not distinguish between LEL and musculoskeletal disease, warranting further investigation. LEL may cause clinically worsened QoL. We demonstrate moderate to strong correlation between questionnaires measuring LEL and QoL.

Disclosures Dr Eriksson reports conflicts of interest: receiving consultation fees from Intuitive Surgical and Astra Zeneca. No other authors report conflicts of interests.

http://dx.doi.org/10.1136/ijgc-2023-ESGO.750

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.